Please login to the form below

Not currently logged in
Email:
Password:

Qtern

This page shows the latest Qtern news and features for those working in and with pharma, biotech and healthcare.

AZ gets US approval for diabetes combo Qtern

AZ gets US approval for diabetes combo Qtern

AZ gets US approval for diabetes combo Qtern. Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015. ... The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015.

Latest news

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    And two other new launches, Bevespi (glycopyrrolate and formoterol fumarate) for chronic obstructive pulmonary disease (COPD) and combination diabetes therapy Qtern (saxagliptin and dapagliflozin), will also help drive the recovery, said

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    EU clears AZ's FDA-rejected diabetes combination. Approval of two-drug therapy Qtern presents first-to-market advantage in Europe. ... The European Commission has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes that was turned down

  • Gilead, Merck get CHMP backing for new hep C combinations Gilead, Merck get CHMP backing for new hep C combinations

    At its meeting last week the CHMP also gave a green light to AstraZeneca's DPP-4 inhibitor/SGLT2 inhibitor combination Qtern (saxagliptin/dapagliflozin) as a treatment for type 2 diabetes.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics